Drug Trial Radar · NCT01193244
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,560
Actual
Start
Oct 1, 2010
Primary completion
Jan 1, 2014
Study completion Apr 7, 2016
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)
Conditions
- Prostate Cancer
Interventions
OrteronelDrug
Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
PlaceboDrug
Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
PrednisoneDrug
Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-free Survival (rPFS)Time frame: Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years)
- Overall SurvivalTime frame: Baseline until death (up to 4.7 years)
Locations
240 sites in 40 countries. Site status is shown where the registry gives one.
Site not named
Anchorage, Alaska
Site not named
Tucson, Arizona
Site not named
Duarte, California
Site not named
Highland, California
Site not named
Orange, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Deerfield Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Jacksonville, Florida
Site not named
Orlando, Florida
Site not named
Port Saint Lucie, Florida
Site not named
Jeffersonville, Indiana
Site not named
Kansas City, Kansas
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Lansing, Michigan
Site not named
Duluth, Minnesota
Site not named
Corinth, Mississippi
Site not named
Columbia, Missouri
Site not named
Jefferson City, Missouri
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Hackensack, New Jersey
Site not named
East Syracuse, New York
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Kettering, Ohio
Site not named
Tualatin, Oregon
Site not named
Hershey, Pennsylvania
Site not named
Lancaster, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Piitsburgh, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Columbia, South Carolina
Site not named
Chattanooga, Tennessee
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.